Clinical Trial Update: Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of NGM831 as a monotherapy and in combination with pembrolizumab (with or without NGM438) in advanced or metastatic solid tumors; the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endocervical Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• NGM438 (NGM438)
• NGM831 (NGM831)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Pancreatic Cancer, Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING